Edgewise launches children’s trial for muscular dystrophy drug
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has initiated a study of the impact of its flagship muscular dystrophy drug candidate EDG-5506 on children with Duchenne Muscular Dystrophy.
The Phase 2 clinical trial is being conducted at Rare Disease Research LLC in Atlanta. Test subjects are 27 children ages 4 to 9 years.
“We are very pleased to begin this important clinical trial of EDG-5506,” Han C. Phan, head of research at Rare Disease Research LLC, said in a prepared statement. “Having studied EDG-5506 over the past year in individuals with Becker with promising results, I’m excited to see the potential of EDG-5506 in children with Duchenne.”
SPONSORED CONTENT
BOULDER — Edgewise Therapeutics Inc. (Nasdaq: EWTX) has initiated a study of the impact of its flagship muscular dystrophy drug candidate EDG-5506 on children with Duchenne Muscular Dystrophy.
The Phase 2 clinical trial is being conducted at Rare Disease Research LLC in Atlanta. Test subjects are 27 children ages 4 to 9 years.
“We are very pleased to begin this important clinical trial of EDG-5506,” Han C. Phan, head of research at Rare Disease Research LLC, said in a prepared statement. “Having studied EDG-5506 over the past year in individuals with Becker with promising results, I’m excited to see the potential…
Related Posts
-
Edgewise Therapeutics Inc., a Boulder-based muscle disease biopharmaceutical company, increased its research and development spending…
-
Medical-device firm Boulder iQ has nearly doubled its Boulder footprint with the purchase of a…
-
OnKure Inc., a Boulder precision oncology company, and California-based Reneo Pharmaceuticals Inc. have completed a…
-
Mosaic Biosciences Inc., a Boulder drug-discovery company that provides protein and antibody therapeutics research to…
